DE4032096C2 - Use of emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of the active ingredient - Google Patents

Use of emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of the active ingredient

Info

Publication number
DE4032096C2
DE4032096C2 DE19904032096 DE4032096A DE4032096C2 DE 4032096 C2 DE4032096 C2 DE 4032096C2 DE 19904032096 DE19904032096 DE 19904032096 DE 4032096 A DE4032096 A DE 4032096A DE 4032096 C2 DE4032096 C2 DE 4032096C2
Authority
DE
Germany
Prior art keywords
emulsifier
active ingredient
emulsion polymers
pharmaceutical preparations
delayed release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE19904032096
Other languages
German (de)
Other versions
DE4032096A1 (en
Inventor
Achim Dr Goepferich
Geoffrey William James Pro Lee
Horst Prof Dr Ludwig
Achim Dr Schaeffler
Bernd Dr Zierenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim GmbH
Original Assignee
Boehringer Ingelheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim GmbH filed Critical Boehringer Ingelheim GmbH
Priority to DE19904032096 priority Critical patent/DE4032096C2/en
Priority to CA002053005A priority patent/CA2053005A1/en
Priority to DE59107240T priority patent/DE59107240D1/en
Priority to ES91117171T priority patent/ES2084747T3/en
Priority to EP91117171A priority patent/EP0480391B1/en
Priority to DK91117171.8T priority patent/DK0480391T3/en
Priority to AT91117171T priority patent/ATE132877T1/en
Priority to JP3263782A priority patent/JPH04264019A/en
Publication of DE4032096A1 publication Critical patent/DE4032096A1/en
Application granted granted Critical
Publication of DE4032096C2 publication Critical patent/DE4032096C2/en
Priority to GR960400183T priority patent/GR3018795T3/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F6/00Post-polymerisation treatments
    • C08F6/14Treatment of polymer emulsions

Description

Die vorliegende Erfindung betrifft die Verwendung von Emulgatoren befreiter Emulsionspolymerisate in pharmazeutischen Zubereitungen mit verzögerter Wirkstofffreigabe.The present invention relates to the use of emulsifiers liberated emulsion polymers in pharmaceutical preparations with delayed drug release.

Bestimmte Emulsionspolymerisate - wie z. B. - emulsionspolymerisierte Ester der Acrylsäure oder Methacrylsäure - sind in den vergangenen Jahren unverzichtbare Hilfsmittel bei der Herstellung von Pharmazeutika geworden, bei denen für einen Wirkstoff eine Darreichungssform mit verzögerter Wirkstofffreigabe angestrebt wird [H. Determann und R. Lotz, Pharmazeutische Industrie 32 (1970) 469].Certain emulsion polymers - such as B. - emulsion polymerized esters of acrylic acid or Methacrylic acid - are in the past few years indispensable tools in the production of Pharmaceuticals have become active ingredients a dosage form with delayed Drug release is sought [H. Determann and R. Lotz, Pharmaceutical Industry 32 (1970) 469].

Derartige Depotformen erlauben über einen längeren Zeitraum eine gleichbleibende Wirkstofffreisetzung und gestatten es somit, die Anzahl der täglich zu verabreichenden Arzneimittelgaben zu verringern und somit das Therapieschema zu vereinfachen.Such forms of custody allow for a longer one Period of constant drug release and thus allow the number of daily to reduce the amount of medication being administered and thus simplifying the therapy scheme.

Im Laufe der Entwicklung dieser Depotformen sind neben einer Vielzahl Tabletten und Kapseln u. a. auch wirkstoffhaltige Pflaster mit kontrollierter Wirkstofffreigabe beschrieben worden.In the course of developing these depot forms are next to a variety of tablets and capsules u. a. also active substance-containing plasters with controlled Drug release has been described.

Für die Herstellung derartiger Depotformen sind aus dem Stand der Technik ebenfalls zahlreiche Verfahren bekannt.For the production of such depot forms are from the State of the art also numerous processes known.

Zum Beispiel kann die Herstellung in der Weise erfolgen, daß man das Emulsionspolymerisat vom Suspensionsmittel befreit, das so isolierte Polymer mit dem Wirkstoff in einem geeigneten - organischen - Lösungsmittel löst, anschließend das Lösungsmittel abdampft und das feste wirkstoffhaltige Polyacrylat bei einer unter der Glastemperatur des Polymeren liegenden Temperatur vermahlt und das wirkstoffhaltige Polyacrylatpulver entweder unter Verwendung von Tablettierhilfsstoffen zu Tabletten oder in anderer Weise - beispielsweise durch Einbringen in Kapseln - verarbeitet.For example, the manufacture can be done in this way take place that the emulsion polymer from Suspending agent frees the polymer isolated in this way the active ingredient in a suitable - organic - Solvent dissolves, then the solvent  evaporates and the solid active ingredient-containing polyacrylate one below the glass transition temperature of the polymer Grinded temperature and the active ingredient Polyacrylate powder using either Tableting aids to tablets or other Way - for example by placing in capsules - processed.

Auch die Herstellung von wirkstoffhaltigen Pflastern ist aus dem Stand der Technik bekannt; sie erfolgt in analoger Weise [s. Europäische Patentschrift 20 905].Also the production of plasters containing active ingredients is known from the prior art; it takes place in analogously [s. European Patent 20 905].

Für die Herstellung derartiger Zubereitungen geeignete Emulsionspolymere sind - wie schon eingangs erwähnt - Ester der Acryl- oder Methacrylsäure, wie z. B. die kommerziell verfügbaren Produkte mit der übergreifenden Produktbezeichnung Eudragit® der Fa. Röhm, Darmstadt.Suitable for the preparation of such preparations As already mentioned at the beginning, emulsion polymers are Esters of acrylic or methacrylic acid, such as. B. the commercially available products with the overarching Product name Eudragit® from Röhm, Darmstadt.

Derartige Emulsionspolymere werden in der Weise hergestellt, daß das wasserunlösliche Monomere mit Hilfe von Emulgatoren bzw. Tensiden in Wasser emulgiert wird und unter Anwendung üblicher Initiatoren die Polymerisation eingeleitet bzw. durchgeführt wird. Die bei dieser Art der Polymerisation anfallenden Polymerdispersionen sind in vielen Fällen direkt einsetzbar und in Form von Dispersionen verfügbar. Wirkstofffreigabesysteme, die auf der Basis von derartigen Emulsionspolymerisaten hergestellt wurden, weisen jedoch den Nachteil auf, daß die Freigaberate des Wirkstoffs von der thermischen Behandlung des Wirkstofffreigabesystems beim Herstellungsprozeß sowie von der Lagerung abhängen kann.Such emulsion polymers are in the way made that the water-insoluble monomer with Emulsified in water with the aid of emulsifiers or surfactants and using the usual initiators Polymerization is initiated or carried out. The in this type of polymerization In many cases, polymer dispersions are direct usable and available in the form of dispersions. Drug release systems based on such emulsion polymers were prepared have the disadvantage, however, that the release rate of the active ingredient from the thermal treatment of the Drug release system in the manufacturing process as well may depend on storage.

Zwar ist aus der EP 0274 741 ein Verfahren bekannt, das es auf dem Wege der Extraktion erlaubt, ein von Emulgatoren, Tensiden oder Hilfsstoffen befreites Emulsionspolymerisat zur Verfügung zu stellen, jedoch fanden derartig behandelte Polymere noch keinen Eingang in Wirkstofffreigabesysteme.A method is known from EP 0274 741, which is based on the Extraction allowed, one of emulsifiers, surfactants or To provide emulsion polymer-free emulsion materials, however, polymers treated in this way have not yet been incorporated into Drug release systems.

Es ist daher die Aufgabe der vorliegenden Erfindung Wirkstofffreigabesysteme auf der Basis von Emulsionspolymerisaten - insbesondere auf der Basis von Polyacrylsäureestern bzw. Polymethacrylsäureestern - zur Verfügung zu stellen, die die oben beschriebene Abhängigkeit nicht aufweisen und außerdem auch nach längerer Lagerzeit und unterschiedlichen Lagerungsbedingungen eine im wesentlichen identische Freigabecharakteristik besitzen.It is therefore the object of the present invention Drug release systems based on Emulsion polymers - especially based on Polyacrylic acid esters or polymethacrylic acid esters - to provide the one described above Not showing dependency and also after longer storage time and different Storage conditions are essentially identical Have release characteristics.

Überraschenderweise wurde nun gefunden, daß die Abhängigkeit der Freigaberate von der thermischen Vorbehandlung während des Herstellungsverfahrens, die im Freigabeverhalten von Wirkstofffreigabesystemen beobachtet werden konnten, auf die Anwesenheit des Emulgators zurückzuführen ist.Surprisingly, it has now been found that the Dependence of the release rate on the thermal Pretreatment during the manufacturing process, the in the release behavior of drug release systems could be observed on the presence of the Emulsifier.

Erfindungsgemäß werden die bei der Herstellung von Wirkstofffreigabesystemen eingesetzten Emulsionspolymere vom Emulgator befreit und daraus - mit an sich bekannten Verfahren - die entsprechenden emulgatorfreien Wirkstofffreigabesysteme hergestellt. According to the invention in the manufacture of Drug release systems used Emulsion polymers freed from the emulsifier and therefrom - with methods known per se - the corresponding emulsifier-free drug delivery systems.  

Für das Entfernen des Emulgators bzw. der extrahierbaren Hilfsstoffe kommen mehrere Verfahren in Betracht. Prinzipiell wird das Emulsionspolymerisat mit einem Extraktionsmittel behandelt, in dem sich das Polymer selbst nicht löst.For removing the emulsifier or extractable excipients come in several processes Consideration. In principle, the emulsion polymer is used an extractant in which the Polymer itself does not dissolve.

Für die erfindungsgemäßen Extraktionsverfahren wird vorzugsweise Wasser eingesetzt.For the extraction process according to the invention preferably water used.

Es ist jedoch in Abhängigkeit von der Art des eingesetzten Polymeren - möglich jedes andere Lösungsmittel bzw. Lösungsmittelgemisch einzusetzen, in dem das Polymere selbst nicht löslich ist.However, it is dependent on the type of polymers used - possible any other Use solvent or solvent mixture in which the polymer itself is not soluble.

Zur Durchführung der Extraktion besteht zum einen die Möglichkeit, den Emulgator aus der handelsüblichen Emulsion durch Ausfällen des Polymers zu entfernen.On the one hand there is the procedure for performing the extraction Possibility to remove the emulsifier from the commercially available Remove the emulsion by precipitating the polymer.

Dies kann mittels üblicher Verfahren, wie z. B. durch Ausfällen mit einem geeigneten Lösungsmittel oder einer Säure, durch Aussalzen, Ausfrieren oder Extraktion erreicht werden.This can be done using conventional methods such. B. by Precipitation with a suitable solvent or Acid, by salting out, freezing out or extraction can be achieved.

Eine weitere Möglichkeit besteht darin, den Emulgator bzw. den/die Hilfsstoffe - nach Abtrennen des Dispersionsmittels - aus dem Polymer zu entfernen. Dazu bieten sich beispielsweise folgende Verfahren an:Another option is to use the emulsifier or the auxiliary material (s) - after removing the Dispersant - to be removed from the polymer. To For example, the following methods are available:

Gleichgewichtsextraktion, Soxleth-Verfahren, Säulenextraktion oder Dialyse.Equilibrium extraction, Soxleth method, Column extraction or dialysis.

Alternativ sind andere Trennverfahren - wie z. B. die Zentrifugation geeignet. Alternatively, other separation methods - such as. B. the Suitable for centrifugation.  

Bevorzugt wird die Extraktion des getrockneten Acrylats (Eudragit NE 30 D®).The extraction of the dried acrylate is preferred (Eudragit NE 30 D®).

Dabei wird das getrocknete Acrylat in einer geeigneten Apparatur zerkleinert bzw. gemahlen und mit Wasser, das ständig erneuert wird, extrahiert. Bevorzugt wird der Emulgator durch Ausfrieren des entsprechenden Emulsionspolymeren und anschließendes Auftauen sowie Waschen mit einem geeigneten Lösungsmittel - vorzugsweise Wasser - entfernt.The dried acrylate is in a suitable Equipment crushed or ground and with water that is constantly renewed, extracted. The is preferred Emulsifier by freezing the corresponding one Emulsion polymers and subsequent thawing as well Washing with a suitable solvent - preferably water - removed.

Die Herstellung der Wirkstofffreigabesysteme ist - wie schon erwähnt - aus dem Stand der Technik bekannt und u. a. in der Deutschen Offenlegungsschrift 33 14 003 sowie in der Europäischen Patentschrift 0 086 997, auf die hiermit inhaltlich Bezug genommen wird, beschrieben.The manufacture of the drug delivery systems is - how already mentioned - known from the prior art and u. a. in German Offenlegungsschrift 33 14 003 as well as in European Patent 0 086 997 which is hereby incorporated by reference.

Als Trägermaterial sind neben den eingangs erwähnten Polymeren auch solche Polymere geeignet, die sich nach dem Emulsionspolymerisationsverfahren herstellen lassen, wie z. B. PVC, Polylactide, Polystyrol, Polyvinylacetat, Polybutadien, Polyacrylnitril, Polyvinylpyrriolidon, Polyvinylester, Polyvinylether und deren Copolymere. Bevorzugt sind Polymere auf der Basis von Estern der Acryl- und/oder der Methacrylsäure.In addition to those mentioned at the beginning, the carrier material is Polymers are also suitable for those polymers which are based on the emulsion polymerization process leave, such as B. PVC, polylactide, polystyrene, Polyvinyl acetate, polybutadiene, polyacrylonitrile, Polyvinyl pyrriolidone, polyvinyl ester, polyvinyl ether and their copolymers. Polymers are preferred on the Basis of esters of acrylic and / or Methacrylic acid.

Besonderes bevorzugt sind emulsionspolymerisierte Copolymerisate von Methyl- und/oder Ethylestern der Acryl- und Methacrylsäure.Emulsion-polymerized are particularly preferred Copolymers of methyl and / or ethyl esters Acrylic and methacrylic acid.

Claims (1)

Verwendung eines Emulsionspolymerisates, das unter Anwendung eines Extraktionsmittels, in dem das Emulsionspolymerisat nicht löslich ist, von Emulgatoren oder Tensiden und anderen in dem Lösungsmittel lösbaren Hilfsstoffen befreit wurde, als Wirkstofffreigabesystem.Use of an emulsion polymer using a Extractant in which the emulsion polymer is not soluble, from Emulsifiers or surfactants and others soluble in the solvent Auxiliaries were exempted as an active ingredient release system.
DE19904032096 1990-10-10 1990-10-10 Use of emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of the active ingredient Expired - Fee Related DE4032096C2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE19904032096 DE4032096C2 (en) 1990-10-10 1990-10-10 Use of emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of the active ingredient
CA002053005A CA2053005A1 (en) 1990-10-10 1991-10-08 Emulsifier-free emulsion polymers
ES91117171T ES2084747T3 (en) 1990-10-10 1991-10-09 EMULSION POLYMERS RELEASED FROM EMULSIONANTS IN PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE, AND THEIR PREPARATION.
EP91117171A EP0480391B1 (en) 1990-10-10 1991-10-09 Emulsion-free emulsion polymers in sustained-release pharmaceutical compositions and their production
DE59107240T DE59107240D1 (en) 1990-10-10 1991-10-09 Emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of active ingredients and their production
DK91117171.8T DK0480391T3 (en) 1990-10-10 1991-10-09 Emulsifier-free emulsion polymers, their preparation and their use in extended-release pharmaceutical preparations
AT91117171T ATE132877T1 (en) 1990-10-10 1991-10-09 EMULGATOR-FREE EMULSION POLYMERS IN PHARMACEUTICAL PREPARATIONS WITH DELAYED RELEASE OF ACTIVE INGREDIENTS AND THEIR PRODUCTION
JP3263782A JPH04264019A (en) 1990-10-10 1991-10-11 Emulsified polymer containing no emulsion manufacture thereof and preparation of active substance gradual release medicine containing the same
GR960400183T GR3018795T3 (en) 1990-10-10 1996-01-25 Emulsion-free emulsion polymers in sustained-release pharmaceutical compositions and their production

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19904032096 DE4032096C2 (en) 1990-10-10 1990-10-10 Use of emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of the active ingredient
DE4042479 1990-10-10

Publications (2)

Publication Number Publication Date
DE4032096A1 DE4032096A1 (en) 1992-04-23
DE4032096C2 true DE4032096C2 (en) 1995-03-30

Family

ID=25897589

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19904032096 Expired - Fee Related DE4032096C2 (en) 1990-10-10 1990-10-10 Use of emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of the active ingredient

Country Status (1)

Country Link
DE (1) DE4032096C2 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764709B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8764786B2 (en) 2002-09-30 2014-07-01 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US8777926B2 (en) 2004-04-21 2014-07-15 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasel or paranasal structures
US8858586B2 (en) 2004-04-21 2014-10-14 Acclarent, Inc. Methods for enlarging ostia of paranasal sinuses
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8905922B2 (en) 2004-04-21 2014-12-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
US9463068B2 (en) 2007-05-08 2016-10-11 Acclarent, Inc. Methods and devices for protecting nasal turbinates
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9572480B2 (en) 2006-09-15 2017-02-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US10349971B2 (en) 2011-06-29 2019-07-16 CARDINAL HEALTH SWITZERLAND 515 GmbH System and method for dilating and adjusting flexibility in a guiding device
US11589742B2 (en) 2004-04-21 2023-02-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US11850120B2 (en) 2007-12-20 2023-12-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167682A1 (en) 2004-04-21 2007-07-19 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US20070208252A1 (en) 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US20190314620A1 (en) 2004-04-21 2019-10-17 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US7649067B2 (en) 2005-10-19 2010-01-19 Wacker Polymers, L.P. Process of making a vinyl ester based polymer latex composition
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
CN102112040B (en) 2008-07-30 2015-04-01 阿克拉伦特公司 Paranasal ostium finder devices and methods
CN103623498B (en) 2008-09-18 2015-12-30 阿克拉伦特公司 Be used for the treatment of the method and apparatus of otorhinolaryngology disease
US20100241155A1 (en) 2009-03-20 2010-09-23 Acclarent, Inc. Guide system with suction
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (en) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim PHARMACEUTICAL PREPARATION IN THE FORM OF A POLYACRYLATE FILM
DE3204551A1 (en) * 1982-02-10 1983-08-18 Boehringer Ingelheim KG, 6507 Ingelheim METHOD FOR PRODUCING A PHARMACEUTICAL PREPARATION IN THE FORM OF A POLYACRYLATE FILM
DE3314003A1 (en) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim DIVISIBLE TABLET WITH DELAYED ACTIVE SUBSTANCE RELEASE AND METHOD FOR THE PRODUCTION THEREOF
DE3789220T2 (en) * 1986-12-27 1994-06-09 Kanegafuchi Chemical Ind Process for obtaining polymer agglomerates as dry powders or granules.

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8740929B2 (en) 2001-02-06 2014-06-03 Acclarent, Inc. Spacing device for releasing active substances in the paranasal sinus
US8764786B2 (en) 2002-09-30 2014-07-01 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US9457175B2 (en) 2002-09-30 2016-10-04 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US9241834B2 (en) 2004-04-21 2016-01-26 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US8777926B2 (en) 2004-04-21 2014-07-15 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasel or paranasal structures
US8852143B2 (en) 2004-04-21 2014-10-07 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US8858586B2 (en) 2004-04-21 2014-10-14 Acclarent, Inc. Methods for enlarging ostia of paranasal sinuses
US11589742B2 (en) 2004-04-21 2023-02-28 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US8905922B2 (en) 2004-04-21 2014-12-09 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, nose and/or throat
US9468362B2 (en) 2004-04-21 2016-10-18 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US9055965B2 (en) 2004-04-21 2015-06-16 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9370649B2 (en) 2004-04-21 2016-06-21 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US8764709B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US9220879B2 (en) 2004-04-21 2015-12-29 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US9308361B2 (en) 2005-01-18 2016-04-12 Acclarent, Inc. Implantable devices and methods for treating sinusitis and other disorders
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US8968269B2 (en) 2005-09-23 2015-03-03 Acclarent, Inc. Multi-conduit balloon catheter
US9198736B2 (en) 2006-05-17 2015-12-01 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9572480B2 (en) 2006-09-15 2017-02-21 Acclarent, Inc. Methods and devices for facilitating visualization in a surgical environment
US9463068B2 (en) 2007-05-08 2016-10-11 Acclarent, Inc. Methods and devices for protecting nasal turbinates
US11850120B2 (en) 2007-12-20 2023-12-26 Acclarent, Inc. Eustachian tube dilation balloon with ventilation path
US9072626B2 (en) 2009-03-31 2015-07-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US10349971B2 (en) 2011-06-29 2019-07-16 CARDINAL HEALTH SWITZERLAND 515 GmbH System and method for dilating and adjusting flexibility in a guiding device
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis

Also Published As

Publication number Publication date
DE4032096A1 (en) 1992-04-23

Similar Documents

Publication Publication Date Title
DE4032096C2 (en) Use of emulsifier-free emulsion polymers in pharmaceutical preparations with delayed release of the active ingredient
EP0387782B1 (en) Solid pharmaceutical preparations and process for their manufacture
EP1200521B1 (en) Dispersion comprising a non-ionic emulsifier
DE3024858C2 (en) Process for the manufacture of a sustained-release pharmaceutical preparation of a solid medicinal material
EP0391172B1 (en) Transdermal therapeutic system with an increased rate of flow of medicament and method for its manufacture
EP0122574B2 (en) Divisible tablet with sustained release of the active ingredient, and process for its production
EP0058765B1 (en) Coating soluble or swellable in gastric juice, and its use in a process for coating pharmaceutical preparations
EP1227801A2 (en) Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients
EP0563731B1 (en) Medicaments containing polyhydroxymethylene-derivatives, process for their manufacture and use thereof
DE3822459A1 (en) WATER-INSOLUBLE POLYPEPTIDES
DE1949894B2 (en) SOLID OR GEL-SHAPED MEDICINAL FORM WITH DELAYED SUBSTANCE RELEASE
EP1020181A1 (en) Process for producing pellets with a pharmaceutical agent content of up to 90% w/w
EP1317254B1 (en) Sustained release particle dispersion
DE2636559C2 (en) Stable preparation for the uniform release of a pharmaceutical compound
EP0167909B2 (en) Solid pharmaceutical preparations containing dihydropyridine, and process for their manufacture
DE19916352A1 (en) Removal of enveloped viruses from blood, plasma or serum
DE1123437B (en) Process for the manufacture of drug forms
DE60119905T2 (en) Process for the preparation of solid dispersions
DE2439538C3 (en) Process for the manufacture of orally administered drugs with delayed release of action
EP0480391B1 (en) Emulsion-free emulsion polymers in sustained-release pharmaceutical compositions and their production
EP1206253B1 (en) Pharmaceutical preparations containing nanosols of chitosan, and their preparation
DE69823299T2 (en) A process for the preparation of bromazepam-containing pharmaceutical compositions in the form of spherical pills or granules for controlled and sustained release and pharmaceutical compositions obtained by the process
AT214573B (en)
DE2449384A1 (en) METHOD OF MANUFACTURING MEDICINAL CONES
DE1810705A1 (en) Vitamin preparations stabilised with subst - xanthines

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8172 Supplementary division/partition in:

Ref country code: DE

Ref document number: 4042479

Format of ref document f/p: P

Q171 Divided out to:

Ref document number: 4042479

Ref country code: DE

AH Division in

Ref country code: DE

Ref document number: 4042479

Format of ref document f/p: P

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee